Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

- Revenues From Continuing Operations Increase 25 Percent to $62.6 Million -

- Conference Call Today at 4:30 p.m. Eastern Time -

INCLINE VILLAGE, Nev., May 7 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2009.

Total revenues from continuing operations for the first quarter of 2009 were $62.6 million, a 25 percent increase from $50.2 million for the same period in 2008. The increase was primarily due to increases in royalty revenues driven by higher product sales of Avastin(R), Herceptin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by Elan Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by MedImmune, Inc.

"We were pleased to begin fulfilling the goal of income distribution to stockholders by paying our first post-spin-off dividend in April, a result of the revenues and profits PDL is generating from royalties on a diversified portfolio of successful products," said John McLaughlin, president and chief executive officer of PDL BioPharma. "Our new and focused strategy seeks to optimize our assets to benefit stockholders without the diversion, expense, and considerable risk of research and development."

Total general and administrative expenses from continuing operations in the first quarter of 2009 were $4.7 million compared with $12.7 million in the first quarter of 2008. The decrease was primarily driven by the Company's reduced cost structure. Significant expense items for the first quarter of 2009 included $1.6 million in legal fees for patent prosecution, patent defense and corporate complia
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research ... of the "Spectroscopy Equipment and Accessories ... to their offering. This ... Equipment and Accessories in US$ Thousands by ... spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), ... technologies and products for advanced microarray diagnostics, today announced ... August 22 at 2:00 pm ET.  ... provide a brief review of SQI,s recent commercialization progress ... diagnostics industry veteran recently appointed to the Board of ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight is ... HIV infection and the number of deaths due to AIDS ... across the globe. It has been estimated that the death ... 2013, with the rates for children being even much lower. ... rates has been the improved access to antiretroviral drugs and ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... tiny man with giant ideas. Ill never forget the one and ... a conference of business executives in Cambridge, Massachusetts. There were one ... for a keynote, Drucker spoke immediately after lunch. He had to ... effortlessly for almost two hours. No Powerpoint. No props. No nonsense. ...
... The City of Madison has been awarded the top ... for Digital Government's 2005 Digital Cities Survey, an ... technology. The annual survey is conducted by the Center ... www.cityofmadison.com , allows visitors access to features such as ...
... and marketers have been hyping any time, anywhere computing for ... starting a technology company, anywhere needs to be spittin distance ... or Boston. You might get away setting up shop in ... well, there is no beyond that. , ,The bias is ...
Cached Biology Technology:Praise for the principles of Peter 2Praise for the principles of Peter 3Praise for the principles of Peter 4Does location matter anymore? 2Does location matter anymore? 3
(Date:8/19/2014)... world, leprosy and tuberculosis live side-by-side. Worldwide there ... year, with nearly all of them occurring where ... Bacille Calmette-Guerin, or BCG, provides only partial protection ... potent vaccine is needed to combat both diseases. ... against both diseases., In a study published in ...
(Date:8/19/2014)... Scientists at the Houston Methodist Research Institute have figured ... using a pipette -- a common laboratory tool that,s ... preliminary test results in a recent issue of the ... "Studying single cells and their unique functions has become ... faculty member Lidong Qin, Ph.D., the project,s principal investigator. ...
(Date:8/19/2014)... UTSA researchers has been awarded a nearly $40,000 grant ... (NCPTT), an office of the National Park Service (NPS) ... fund a one-year study of the energy efficiency and ... in hot, humid climates. , Radiant barriers are reflective ... reflect heat back, thereby reducing the amount of heat ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... is available in Spanish . , A ... has been released by Agricultural Research Service (ARS) scientists and ... aquatic plant native to South America that has infested freshwater ... in the southeastern United States. The plant is a real ...
... CITY, Calif. and WEST PALM BEACH, Fla. ... global provider of authentication and endpoint protection solutions and ... (EMR) and Discharge Systems for Emergency Rooms and Urgent ... biometrics from DigitalPersona into the ScriptRx System. Designed for ...
... venue for the 3rd Baltic Congress of Osteoporosis which ... to be held in English, is jointly organized by ... Osteoporosis Foundation, Lithuanian Association of Metabolic Bone Diseases and ... most disabling conditions of older adults and elderly. These ...
Cached Biology News:Scientists release biocontrol for water hyacinth 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 3ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 4
... The x2 Dual-Binary Analytical System more than ... LC and LC/MS. The fast analysis cycles ... by up to 100% in tandem mode. ... multi-dimensional mode. Using backflush or heartcut configurations, ...
... for immune complex disruption (ICD) of antigen/antibody ... a combination of low pH and heat. ... to microplate wells which are coated with ... HIV-1 p24. The immobilized monoclonal antibody captures ...
Request Info...
... EVOlyzer is Tecans new Enzyme-Linked Immunosorbent Assay ... Freedom EVOlyzer is a dedicated EVO platform ... reader, washer and incubation units operated by ... EVOlyzer is available in three sizes - ...
Biology Products: